DexCom (NASDAQ:DXCM) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

DexCom (NASDAQ:DXCM) had its target price increased by equities researchers at Royal Bank Of Canada from $85.00 to $90.00 in a research note issued on Friday,Benzinga reports. The firm currently has an “outperform” rating on the medical device company’s stock. Royal Bank Of Canada’s price target indicates a potential upside of 7.46% from the company’s previous close.

DXCM has been the subject of several other reports. Bank of America lowered their price objective on shares of DexCom from $100.00 to $80.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Raymond James Financial reiterated a “strong-buy” rating and issued a $94.00 target price on shares of DexCom in a report on Friday. BTIG Research reissued a “buy” rating and set a $90.00 price target (up from $80.00) on shares of DexCom in a research report on Friday. UBS Group set a $96.00 price target on DexCom and gave the company a “buy” rating in a research note on Tuesday. Finally, Wells Fargo & Company lifted their price objective on DexCom from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $87.96.

DexCom Trading Up 12.4%

NASDAQ DXCM traded up $9.21 on Friday, hitting $83.75. 7,863,549 shares of the stock were exchanged, compared to its average volume of 5,235,423. DexCom has a 52-week low of $54.11 and a 52-week high of $87.00. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. The stock has a fifty day moving average price of $72.91 and a two-hundred day moving average price of $69.10. The firm has a market capitalization of $32.32 billion, a P/E ratio of 35.76, a P/E/G ratio of 1.24 and a beta of 1.45.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.61 by $0.09. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The company had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.29 billion. During the same period in the prior year, the firm posted $0.48 EPS. The firm’s revenue was up 13.1% compared to the same quarter last year. Research analysts forecast that DexCom will post 2.57 EPS for the current fiscal year.

Insider Buying and Selling

In other DexCom news, Director Bridgette P. Heller sold 1,012 shares of the company’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total transaction of $60,730.12. Following the completion of the sale, the director owned 25,007 shares in the company, valued at $1,500,670.07. This represents a 3.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,759 shares of the stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $72.00, for a total value of $1,926,648.00. Following the sale, the insider directly owned 382,482 shares in the company, valued at $27,538,704. This trade represents a 6.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 98,506 shares of company stock valued at $7,205,258 over the last ninety days. Company insiders own 0.28% of the company’s stock.

Institutional Investors Weigh In On DexCom

Hedge funds have recently made changes to their positions in the stock. Tema ETFs LLC lifted its position in shares of DexCom by 14.2% during the second quarter. Tema ETFs LLC now owns 21,664 shares of the medical device company’s stock valued at $1,459,000 after buying an additional 2,688 shares during the last quarter. E. Ohman J or Asset Management AB grew its position in shares of DexCom by 18.9% in the 2nd quarter. E. Ohman J or Asset Management AB now owns 113,204 shares of the medical device company’s stock worth $7,624,000 after buying an additional 18,012 shares during the last quarter. Paladin Wealth LLC raised its stake in shares of DexCom by 17.4% during the 2nd quarter. Paladin Wealth LLC now owns 9,338 shares of the medical device company’s stock worth $629,000 after acquiring an additional 1,386 shares in the last quarter. Arista Wealth Management LLC bought a new position in shares of DexCom during the 2nd quarter worth approximately $337,000. Finally, Sax Wealth Advisors LLC lifted its position in DexCom by 46.1% during the second quarter. Sax Wealth Advisors LLC now owns 17,001 shares of the medical device company’s stock valued at $1,068,000 after acquiring an additional 5,364 shares during the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom News Roundup

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Quarterly results exceeded expectations: DexCom reported adjusted earnings of $0.70 per share versus the $0.61 consensus estimate, while revenue rose 13.1% year over year to $1.31 billion, ahead of the $1.29 billion forecast. DexCom Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Full-year outlook was raised: Management lifted its 2026 revenue forecast to approximately $5.18 billion-$5.25 billion, reflecting sustained demand for continuous glucose monitors and confidence in continued growth. DexCom also expects nearly half of U.S. users to convert to its G7 15 Day system by year-end. DexCom Raises 2026 Revenue Outlook
• Positive Sentiment: Growth remained broad-based: Second-quarter U.S. revenue reached $933 million, up 11%, while international revenue grew substantially, supporting the company’s expansion narrative for its CGM, G7 15 Day and Stelo platforms. DexCom Raises Annual Revenue Forecast
• Positive Sentiment: Analyst sentiment improved: Wells Fargo raised its price target to $90 and maintained an overweight rating, while Benchmark raised its target to $82 and assigned a buy rating. UBS also reaffirmed its buy rating with a $96 target, adding support to the bullish reaction.
• Neutral Sentiment: Institutional positioning was mixed: Hundreds of institutions adjusted their holdings, with large additions from Wellington Management, AllianceBernstein and UBS offset by sizable reductions from Jennison Associates and Nuveen.
• Negative Sentiment: Insider activity was a cautionary signal: Company insiders reported 14 open-market sales and no purchases during the past six months. This may temper enthusiasm but was outweighed by the earnings beat and raised outlook.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.